Navigation Links
Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
Date:11/7/2012

177542Total assets 

$  110,134$  149,700Liabilities and stockholders' equity Current liabilities:Accounts payable and accrued expenses 

$   17,775$
4,277Deferred revenue, current portion 

3,4293,429Total current liabilities 

21,2047,706Deferred revenue, less current portion 

39,42942,000Other long-term liabilities 

140288Commitments and contingenciesStockholders' equity:Preferred stock, $.001 par value, 10,000,000 shares authorized at September 30, 2012 and December 31, 2011; noshares issued and outstanding atat September 30, 2012 and December 31, 2011--Common stock, $.001 par value, 300,000,000 sharesauthorized at September 30, 2012 and December 31, 2011;70,727,827 and 61,285,514 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively

7161Additional paid-in capital 

453,624446,357Accumulated other comprehensive income (loss)

15(2)Accumulated deficit

(404,349)(346,710)Total stockholders' equity 

49,36199,706Total liabilities and stockholders' equity 

$  110,134$  149,700 Orexigen Therapeutics, Inc.Statements of Operations(In thousands, except per share amounts)(Unaudited)Three Months Ended Nine Months Ended September 30, September 30, 2012201120122011Revenues:Collaborative agreement 

$
857$
857$
2,571$
2,571License revenue ---971Total revenues 

8578572,5713,542Operating expenses:Research and development 

25,8061,53945,42811,237General and administrative 

5,6513,90714,90515,870Total operating expenses 

31,4575,44660,33327,107Loss from operations 

(30,600)(4,589)(57,762)(23,565)Other income (expense):Interest income 

36912535Interest expense 

--(2)(221)Total other income (expense) <
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... WOONSOCKET, R.I. , Jan. 15, 2014 MultiCell ... has filed a U.S. provisional patent application concerning composition ... formulations to achieve targeted tumor cell death.  ... very small noncoding double stranded RNA molecules (VSRNAs) which ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... (Prime), a thought leader in pharmacy benefit management, has ... 2011 Transparency in Pharmaceutical Purchasing Standards(SM) (TIPPS) certification from ... year that Prime has received this certification. ... (PBMs) that have agreed to provide pharmacy cost information ...
... Oct. 19 Ingenuity® Systems, the leading provider ... TransMed Systems, a translational medicine software and services ... and XB Bio-Integration Suite (XB-BIS).  Researchers can now ... managed and statistically analyzed by XB-BIS, directly into ...
Cached Medicine Technology:Prime Therapeutics Receives 2011 TIPPS Certification 2Ingenuity Systems and TransMed Systems Integrate Software to Support Personalized Medicine Research 2
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... EAST LANSING, Mich. - With the help of a ... Michigan State University is creating a cross-discipline, mentored program ... in women,s health., MSU,s new Building Interdisciplinary Research Careers ... Department of Medicine in the College of Human Medicine, ...
... MD, MPH, an endocrinologist at Nationwide Children,s Hospital, has ... customized text messages to remind adolescent diabetes patients about ... study, Dr. Dyer found an increase in overall treatment ... Dyer began developing this pilot study after realizing the ...
... , THURSDAY, July 29 (HealthDay News) -- Although millions ... ward off osteoporosis, New Zealand researchers say the supplements have ... increase in the risk for heart attack among older people. ... suggest that people get their required calcium, if possible, from ...
... is a protein that is expressed in and on ... and antigen presenting cells. This protein is known for ... response. Additionally, Professor Shachar,s lab has previously shown that ... the immune system, and that its stimulation by its ...
... influencing both morbidity and recovery after surgery. The ... intervention, which may prevent later complications. A traditional ... to identify significant weight loss over time, significantly ... nutritional factor levels and functional measurements of muscle ...
... most common cancers worldwide, particularly in China. However, ... to treat. It is important to screen for ... possess anti-cancer properties. These dietary compounds may modify ... proliferation and apoptosis. Galangin could inhibit the methoxyresorufin ...
Cached Medicine News:Health News:MSU targets women's health research with $2.5 million grant 2Health News:Pilot study supports adolescent diabetes patients through personalized text messages 2Health News:Calcium Supplements Linked to Boost in Heart Attack Risk 2Health News:Calcium Supplements Linked to Boost in Heart Attack Risk 3Health News:Calcium Supplements Linked to Boost in Heart Attack Risk 4Health News:How to detect malnutrition in patients effectively? 2
This is a reduced form of the 100 Hue test and L'Anthony New Color Test. The 40 Hue test is obviously quicker to administer. It provides extensive chromatic sensitivity and gives a quantitative score...
... Farnsworth 100 Hue Test comes boxed in clear ... the potential for test disruption by holding ... Hue test from Richmond Products includes 93 color ... durable laminated score template for copying, a supply ...
... Strep A test is as easy as 1-2-3: ... results. Increase patient satisfaction with rapid information before ... your patient immediately with the appropriate therapy; no ... Use: ,The NOW® Strep A Test is a ...
Single Use Loading Units (SULU's) Knifeless for use with MULTIFIRE ENDO GIA™ 30 12 mm (Single Use Staplers with Titanium Staples)....
Medicine Products: